MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors
Key Highlights
- ➤MacroGenics (MGNX) appoints Emil Kuriakose and Michael Vasconcelles independent directors
- ➤Appointments effective October 30, 2026, strengthen oncology development and regulatory expertise
- ➤Kuriakose previously led clinical, regulatory and portfolio strategy at Terns Pharmaceuticals
- ➤Vasconcelles previously headed research and development at Day One Biopharmaceuticals
Expert Statements
Eric Risser, President and Chief Executive Officer of MacroGenics
“We are pleased to welcome Emil and Mike to the MacroGenics Board. Both bring extensive oncology drug development experience, including leadership across clinical development, regulatory strategy and portfolio management. Their perspectives will be valuable as we advance our pipeline of innovative product candidates and execute on our long-term strategic objectives.”
William Heiden, Chair of the MacroGenics Board of Directors
“Emil and Mike are distinguished industry leaders with established track records guiding innovative biotechnology companies through critical stages of growth and delivering substantial shareholder value. Their experience and strategic insight will further strengthen our Board as we work to position MacroGenics for long-term success.”
ROCKVILLE, MD, Nov. 03, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointments of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors to its Board of Directors, effective October 30, 2026.
“We are pleased to welcome Emil and Mike to the MacroGenics Board,” said Eric Risser, President and Chief Executive Officer of MacroGenics. “Both bring extensive oncology drug development experience, including leadership across clinical development, regulatory strategy and portfolio management. Their perspectives will be valuable as we advance our pipeline of innovative product candidates and execute on our long-term strategic objectives.”
Get started
Create a free account to read the full story.